Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clemastine in Preterm Neonates With White Matter Injury (WRAP)
NCT07688746Phase 1Recruiting
- Start
- Jul 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of clemastine in white matter injury (WMI) (4 arms). Primary endpoint: Dose Limiting Toxicity at 30 days. Started Jul 2026; status: recruiting.
02
Drugs
clemastine
03
Conditions
white matter injury (WMI)
Beyond the preview
Go deeper on NCT07688746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688746.